Functional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Department of Neurosurgery, Shohada Tajrish Hospital, Tehran, Iran.
Functional Neurosurgery Research Center, Shohada Tajrish Comprehensive Neurosurgical Center of Excellence, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
World Neurosurg. 2024 Jun;186:51-61. doi: 10.1016/j.wneu.2024.01.161. Epub 2024 Feb 5.
Radiotherapy (RT) is a feasible adjuvant therapeutic option for managing intracranial pathologies. One of the late complications of RT that frequently develops within months following RT is radiation necrosis (RN). Corticosteroids are the first-line therapeutic option for RNs; however, in case of unfavorable outcomes or intolerability, several other options, including bevacizumab, laser interstitial thermal therapy, surgery, and hyperbaric oxygen therapy (HBOT). Our goal was to investigate the feasibility and efficacy of the application of HBOT in RNs following RT and help physicians make decisions based on the latest data in the literature.
We provide a comprehensive review of the literature on the current issues of utilization of HBOT in RNs.
We included 11 studies with a total of 46 patients who underwent HBOT. Most of the cases were diagnosed with brain tumors or arteriovenous malformations. Improvement was achieved in most of the cases.
HBOT is a noninvasive therapeutic intervention that can play a role in adjuvant therapy concurrent with RT and chemotherapy and treating RNs. HBOT resolves the RN through 3 mechanisms, including angiogenesis, anti-inflammatory modulation, and cellular repair. Previous studies demonstrated that HBOT is a feasible and well-tolerated therapeutic option that has shown promising results in improving clinical and radiological outcomes in intracranial RNs. Complications of HBOT are usually mild and reversible.
HBOT is a feasible and effective therapeutic option in steroid-refractory RNs and is associated with favorable outcomes and a low rate of side effects.
放射治疗(RT)是管理颅内病变的一种可行的辅助治疗选择。RT 后数月内经常发生的一种晚期并发症是放射性坏死(RN)。皮质类固醇是治疗 RN 的一线选择;然而,如果治疗效果不佳或无法耐受,还有其他几种选择,包括贝伐单抗、激光间质热疗、手术和高压氧治疗(HBOT)。我们的目标是研究 HBOT 在 RT 后 RN 中的应用的可行性和疗效,并根据文献中的最新数据帮助医生做出决策。
我们对 HBOT 在 RN 中的应用的当前问题进行了全面的文献综述。
我们纳入了 11 项研究,共 46 例接受 HBOT 的患者。大多数病例被诊断为脑肿瘤或动静脉畸形。大多数病例都取得了改善。
HBOT 是一种非侵入性的治疗干预措施,可在 RT 和化疗的辅助治疗以及治疗 RN 中发挥作用。HBOT 通过 3 种机制解决 RN,包括血管生成、抗炎调节和细胞修复。先前的研究表明,HBOT 是一种可行且耐受良好的治疗选择,在改善颅内 RN 的临床和影像学结果方面显示出有希望的结果。HBOT 的并发症通常是轻微且可逆的。
HBOT 是类固醇难治性 RN 的一种可行且有效的治疗选择,与良好的结果和低副作用发生率相关。